Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti‐inflammatory drugs: a Danish real‐world cohort study
暂无分享,去创建一个
L. Skov | L. Iversen | C. Torp-Pedersen | G. Gislason | P. Hansen | R. Gniadecki | S. Kristensen | L Skov | C Torp-Pedersen | R Gniadecki | Ole Ahlehoff | L Iversen | T N Dam | O Ahlehoff | G Gislason | J Lindhardsen | S L Kristensen | S Lasthein | P R Hansen | G. Gislason | J. Lindhardsen | T. N. Dam | S. Lasthein
[1] W. Boehncke,et al. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity , 2011, Experimental dermatology.
[2] C. Lang,et al. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis , 2009, The British journal of dermatology.
[3] Andrea B Troxel,et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. , 2010, European heart journal.
[4] A. Kyrgidis,et al. Biologic therapies for chronic plaque psoriasis and cardiovascular events. , 2011, JAMA.
[5] M. Hochberg,et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis , 2010, Annals of the rheumatic diseases.
[6] L. Jacobsson,et al. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. , 2012, Arthritis and rheumatism.
[7] W. Dixon,et al. What effects might anti-TNFα treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFα in cardiovascular pathophysiology , 2007, Annals of the rheumatic diseases.
[8] E. Coomes,et al. Methotrexate in Atherogenesis and Cholesterol Metabolism , 2011, Cholesterol.
[9] R. Stern,et al. Going beyond associative studies of psoriasis and cardiovascular disease. , 2012, The Journal of investigative dermatology.
[10] L. Skov,et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study , 2011, Journal of Internal Medicine.
[11] Timothy L Lash,et al. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients , 2011, BMC medical research methodology.
[12] A. Menter,et al. Exploring the association between cardiovascular and other disease‐related risk factors in the psoriasis population: the need for increased understanding across the medical community , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.
[13] A. Troxel,et al. The risk of stroke in patients with psoriasis. , 2009, The Journal of investigative dermatology.
[14] A. Kimball,et al. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study , 2011, The British journal of dermatology.
[15] R. Kirsner,et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. , 2005, Journal of the American Academy of Dermatology.
[16] Hisashi Adachi,et al. Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.
[17] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.
[18] L. Skov,et al. Psoriasis Carries an Increased Risk of Venous Thromboembolism: A Danish Nationwide Cohort Study , 2011, PloS one.
[19] A. Menter,et al. Current and future management of psoriasis , 2007, The Lancet.
[20] D. Federman,et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. , 2009, Archives of dermatology.
[21] D. Mozaffarian,et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. , 2011, The American journal of cardiology.
[22] P. Ridker,et al. AJC editor's consensus: psoriasis and coronary artery disease. , 2008, The American journal of cardiology.
[23] S. Schneeweiss,et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. , 2011, JAMA.
[24] P. Kiely,et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. , 2010, Rheumatology.
[25] Frits Mastik,et al. Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque , 2008, Circulation.
[26] J. Tu,et al. ICD-10 adaptations of the Ontario acute myocardial infarction mortality prediction rules performed as well as the original versions. , 2007, Journal of clinical epidemiology.
[27] M. Osler,et al. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. , 2003, Journal of clinical epidemiology.
[28] B. Strober,et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. , 2011, JAMA.
[29] Paul M Ridker,et al. Inflammation in atherosclerosis: from pathophysiology to practice. , 2009, Journal of the American College of Cardiology.
[30] L. Skov,et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. , 2011, European heart journal.
[31] Frank O. Nestle,et al. Mechanisms of Disease: Psoriasis. , 2009 .
[32] L. Skov,et al. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris , 2011, The British journal of dermatology.
[33] E. Berardesca,et al. Effective Therapy with Anti‐TNF‐α in Patients with Psoriatic Arthritis Is Associated with Decreased Levels of Metalloproteinases and Angiogenic Cytokines in the Sera and Skin Lesions , 2007, Annals of the New York Academy of Sciences.
[34] F. Granath,et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients , 2003, European Journal of Epidemiology.
[35] G. Mazzoccoli,et al. Anti-tumor necrosis factor-α therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients , 2010, Internal and emergency medicine.
[36] E. Sijbrands,et al. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. , 2007, Atherosclerosis.
[37] M. Quinn,et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. , 2011, Rheumatology.
[38] T. Truelsen,et al. Validity of Stroke Diagnoses in a National Register of Patients , 2007, Neuroepidemiology.
[39] Daniel B. Shin,et al. Risk of myocardial infarction in patients with psoriasis. , 2006, JAMA.
[40] L. Skov,et al. Prognosis following first‐time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study , 2011, Journal of internal medicine.
[41] P. Ridker. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT) , 2009, Journal of thrombosis and haemostasis : JTH.